Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.X-Chem, a Minnesota-based biotechnology company, has signed a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the discovery of drug candidates against several of Roche's therapeutic targets.
Subscribe to our email newsletter
Under the terms of the agreement, X-Chem is expected to get an upfront and research payments, success-based discovery milestones, and technology access fees from Roche.
Roche is expected to posses the development and commercialisation rights over any product arising from the collaboration, and X-Chem is expected to receive development milestones and royalties based on worldwide sales of the therapeutic products developed by Roche.
Richard Wagner, president and CEO of X-Chem, said: “Entering into our first alliance with a partner such as Roche is exciting for our company. The program that we are developing is expected to establish drug discovery capabilities in the industry.”